Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Maxwell Skor
MS

Maxwell Skor

Morgan Stanley
Wall Street Analyst
★★★☆☆
#2171
on 13Foresight · ranked by our own returns
43%
Success Rate
+0.1%
Average Return
35 of 82 calls profitable · -1.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 43% of Maxwell Skor's ratings turned a profit when each position was held for 1 year — averaging +0.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

107 Buy 26 Hold 0 Sell
Maxwell's Stock Coverage 16 ratings · 2026-11-05
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
INSM
Insmed
 Oct 30, 2026 BUY Strong Buy
+51.3% avg upside
37 analysts
$213.00
89.29% Upside
 -3.3% ·
PHVS
Pharvaris
 Oct 26, 2026 BUY Strong Buy
+67.0% avg upside
15 analysts
$62.00
84.82% Upside
 +8.6% ·
FDMT
4D Molecular Therapeutics
 Oct 21, 2026 HOLD Strong Buy
+185.0% avg upside
17 analysts
 — -9.9% ·
ACHV
Achieve Life Sciences
 Oct 21, 2026 BUY Strong Buy
+128.6% avg upside
16 analysts
$13.00
90.28% Upside
 +4.9% ·
RGNX
RegenXBio
 Oct 20, 2026 BUY Strong Buy
+389.7% avg upside
25 analysts
$18.00
149.93% Upside
 -0.3% ·
ASND
Ascendis Pharma
 Oct 12, 2026 BUY Strong Buy
+12.3% avg upside
29 analysts
$273.00
8.60% Upside
 +11.5% ·
RARE
Ultragenyx Pharmaceutical
 Sep 21, 2026 HOLD Strong Buy
+193.8% avg upside
36 analysts
$20.00
24.29% Upside
 +17.1% ·
CRSP
Crispr Therapeutics AG
 Aug 28, 2026 HOLD Buy
+45.6% avg upside
41 analysts
$60.00
16.75% Upside
 -15.9% ·
TCRX
TScan Therapeutics
 Aug 17, 2026 HOLD Buy
+4293.5% avg upside
12 analysts
 — -73.2% ·
ADAG
Adagene
 Aug 17, 2026 HOLD Strong Buy
+196.4% avg upside
8 analysts
 — -34.5% ·
SANA
Sana Biotechnology
 Aug 17, 2026 BUY Strong Buy
+282.6% avg upside
14 analysts
$12.00
366.87% Upside
 -32.6% ·
MNPR
Monopar Therapeutics Inc
 Aug 17, 2026 BUY Strong Buy
+51.0% avg upside
18 analysts
$130.00
84.85% Upside
 -43.1% ·
BCYC
Bicycle Therapeutics
 Aug 17, 2026 HOLD Strong Buy
+557.2% avg upside
21 analysts
 — -13.0% ·
AVIR
Atea Pharmaceuticals
 Aug 13, 2026 HOLD Buy
+64.2% avg upside
6 analysts
$7.00
70.26% Upside
 -12.0% ·
CYTK
Cytokinetics
 Jul 23, 2026 BUY Strong Buy
+43.4% avg upside
36 analysts
$103.00
63.51% Upside
 -32.2% ·
IVVD
Invivyd
 Nov 20, 2024 BUY Buy
+1291.1% avg upside
8 analysts
$3.55
510.31% Upside
 +212.5% ·
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Maxwell Skor — Frequently Asked Questions
How accurate are Maxwell Skor's stock ratings?
Based on the calls 13Foresight could measure, about 43% of Maxwell's ratings were profitable over a one-year hold, with an average return of +0.3% per rating, or -1.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Maxwell ranked on 13Foresight?
Maxwell Skor is currently ranked #2171 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Maxwell cover?
Maxwell most recently has ratings on INSM, PHVS, FDMT, ACHV, RGNX, ASND, RARE, CRSP, TCRX, ADAG, SANA, MNPR and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.